Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.

NCT05224388 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT05224388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05224388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
Lead sponsor
University Hospital, Ghent
Phase
Observational
Overall status
Completed
Start date
January 1, 2020
Completion date
September 15, 2022
Enrollment
813 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulants and bleeding disorders, covid-19, critical illness, deep vein thrombosis